FDA Grants 'Breakthrough Therapy' Designation to MDMA for PTSD

Published Online: Monday, September 4th, 2017
The FDA has granted a "breakthrough therapy" designation to 3,4-methylenedioxymethamphetamine (MDMA), also known as the street-drug ecstasy, for the treatment of posttraumatic stress disorder (PTSD), and 2 phase 3 trials are in the works, according to a press release from the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS).1

MAPS and the FDA have also reached agreement under the Special Protocol Assessment Process (SPA) for the design of the 2 upcoming phase 3 trials, which will begin enrolling patients in Spring 2018, after the completion of an open-label lead-in training study at phase 3 sites starting this fall.

The phase 3 trials will assess the efficacy and safety of MDMA-assisted psychotherapy in 200-300 participants with PTSD, aged 18 and older, at sites in the US, Canada, and Israel. Participants will be randomly assigned to receive 3 day-long sessions of either MDMA or placebo in conjunction with psychotherapy over a 12-week treatment period, along with 12 associated 90-minute non-drug preparatory and integration sessions. The primary endpoint will be the Clinician Administered PTSD Scale (CAPS-5), as assessed by a blinded pool of independent raters.

In MAPS' completed phase 2 trials with 107 participants, 61% no longer qualified for PTSD after 3 sessions of MDMA-assisted psychotherapy 2 months following treatment. At the 12-month follow-up, 68% no longer had PTSD. All Phase 2 participants had chronic, treatment-resistant PTSD, and had suffered from PTSD for an average of 17.8 years.

Reference
FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Psychotherapy for PTSD, Agrees on Special Protocol Assessment for Phase 3 Trials [news release]. Santa Cruz, Calif. MAPS website. Aug. 26, 2017. http://www.maps.org/news/media/6786-press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd,-agrees-on-special-protocol-assessment-for-phase-3-trials. Accessed Aug. 30, 2017. 

Current Issue

The Educated Patient

Kristen Marjama, DNP, FNP-BC
The National Health Interview Survey in 2014 estimated that 17.7 million adults and 6.3 million children had asthma.
Mary McCormack, MSN, APNC, MPH
The World Gastroenterology Organization describes the prevalence of celiac disease as a “statistical iceberg” in today’s health climate.
Melissa DeCapua, DNP, PMHNP-B-C
Diabetic retinopathy causes more losses of vision worldwide than any other eye disease, affecting 33% of the 285 million individuals suffering from diabetes.
Janet Gilbreath, DNP, MBA, MSN, FNP-BC
Head lice are 6-legged insects about the size of a sesame seed that cling to the scalp and neck and survive by feeding on human blood.
$vacMongoViewPlus$ $vAR$
Contemporary Clinic
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
ONCLive
OTCGuide
Pharmacy Times
Specialty Pharmacy Times
Targeted Oncology
About Us
Advertise
Careers
Contact Us
Feedback
Privacy
Terms & Conditions
Pharmacy Healthcare & Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-257-0701

Copyright Contemporary Clinic 2017
Pharmacy Healthcare & Communications, LLC. All Rights Reserved.